Patents by Inventor Joe Salas
Joe Salas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220243189Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.Type: ApplicationFiled: January 18, 2022Publication date: August 4, 2022Inventors: Vu Phong HONG, Adam R. MEZO, Joe SALAS, Robert PETERS
-
Publication number: 20220233650Abstract: Disclosed herein are methods of treating subjects with hemophilia and low bone mineral density (BMD) with a chimeric protein comprising a coagulation factor and a Fc domain. In certain embodiments, the chimeric protein is rFVIIIFc. In certain embodiments, a subject to be treated has hemophilia A.Type: ApplicationFiled: June 18, 2020Publication date: July 28, 2022Inventors: Susu DUAN, Katalin KIS-TOTH, Gaurav Manohar RAJANI, Joe SALAS
-
Publication number: 20220213200Abstract: The present invention provides antibodies and antigen-binding molecules thereof which specifically bind the ? and/or ? subunits of the non-active form of the GPIIb/IIIIa receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties and used, for example, as targeting moieties. The invention also includes methods for screening for these antibodies, as well as methods of making and methods of using chimeric molecules derived from the antibodies.Type: ApplicationFiled: October 13, 2021Publication date: July 7, 2022Applicant: Biogen MA Inc.Inventors: Joe Salas, Siyuan Tan, Robert Peters
-
Publication number: 20220135959Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.Type: ApplicationFiled: October 7, 2021Publication date: May 5, 2022Inventors: Joe SALAS, Elena KISTANOVA, Vu Phong HONG, Adam R. MEZO, Robert T. PETERS
-
Publication number: 20220089745Abstract: Antibodies and antigen-binding antibody fragments that bind to GPIIb/IIIa and chimeric polypeptides comprising these binding molecules are disclosed. Some of these antibodies and antigen-binding antibody fragments preferentially bind GPIIb/IIIa on activated platelets while others do not show a preference for binding GPIIb/IIIa on resting versus activated platelets. Some of these antibodies and antibody fragments do not inhibit the interaction of GPIIb/IIIa with fibrinogen, while some others do. The disclosed antibodies do not induce platelet activation. Some of these antibodies and antigen-binding antibody fragments are useful in targeting therapeutic agents such as dotting factors to platelets while others are useful in reducing platelet aggregation and/or thrombus formation.Type: ApplicationFiled: June 21, 2021Publication date: March 24, 2022Applicant: Biogen MA Inc.Inventors: Bradley Pearse, Joe Salas, Robert Peters, Christilyn Graff
-
Patent number: 11261437Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.Type: GrantFiled: March 18, 2019Date of Patent: March 1, 2022Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Vu Phong Hong, Adam R. Mezo, Joe Salas, Robert Peters
-
Publication number: 20210355473Abstract: Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasis using these clotting factors.Type: ApplicationFiled: April 5, 2021Publication date: November 18, 2021Inventors: Joe SALAS, Robert PETERS, Alan BITONTI
-
Patent number: 11168316Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.Type: GrantFiled: December 20, 2018Date of Patent: November 9, 2021Assignee: Bioverativ Therapeutics, Inc.Inventors: Joe Salas, Elena Kistanova, Vu Phong Hong, Adam R. Mezo, Robert T. Peters
-
Publication number: 20210292729Abstract: The present invention features inter alia nucleic acid molecules which encode polypeptides comprising a single chain Fc region and the polypeptides they encode. The Fc moieties of these constructs are linked by a cleavable scFc linker which is adjacent to at least one enzymatic cleavage site, e.g., an intracellular processing site. The resulting processed molecules comprise two polypeptide chains and substantially lack the extraneous amino acid sequence found in single chain Fc linker molecule. Methods of making and using these dimeric molecules are also described.Type: ApplicationFiled: January 19, 2021Publication date: September 23, 2021Inventors: Joe SALAS, Robert T. PETERS
-
Publication number: 20210246212Abstract: Antibodies and antibody fragments that specifically bind to glycoprotein IIb/IIIa (GPIIb/IIIa) are disclosed. Chimeric molecules comprising such antibodies or antigen-binding fragments are also disclosed. In addition, methods of using the disclosed antibodies, antibody fragments, and chimeric molecules, e.g., to target agents to platelets and for the treatment or prevention of diseases or disorders are provided.Type: ApplicationFiled: November 12, 2020Publication date: August 12, 2021Inventors: Joe Salas, Karl Hanf, Arjan van der Flier, Bradley R. Pearse
-
Patent number: 10968442Abstract: Chimeric clotting factors which localize the therapeutic to sites of coagulation (e.g., by being targeted to platelets or being activatable at sites of coagulation), have reduced clearance rates, have improved manufacturability, have reduced thrombogenicity, have enhanced activity, or have more than one of these characteristics are described as are methods for making chimeric clotting factors and methods for improving hemostasis using these clotting factors.Type: GrantFiled: July 27, 2016Date of Patent: April 6, 2021Assignee: Bioverativ Therapeutics Inc.Inventors: Joe Salas, Robert Peters, Alan Bitonti
-
Patent number: 10927362Abstract: The present invention features inter alia nucleic acid molecules which encode polypeptides comprising a single chain Fc region and the polypeptides they encode. The Fc moieties of these constructs are linked by a cleavable scFc linker which is adjacent to at least one enzymatic cleavage site, e.g., an intracellular processing site. The resulting processed molecules comprise two polypeptide chains and substantially lack the extraneous amino acid sequence found in single chain Fc linker molecule. Methods of making and using these dimeric molecules are also described.Type: GrantFiled: November 21, 2017Date of Patent: February 23, 2021Assignee: BIOVERATIV THERAPEUTICS INC.Inventors: Joe Salas, Robert T. Peters
-
Patent number: 10875924Abstract: Antibodies and antibody fragments that specifically bind to glycoprotein IIb/IIIa (GPIIb/IIIa) are disclosed. Chimeric molecules comprising such antibodies or antigen-binding fragments are also disclosed. In addition, methods of using the disclosed antibodies, antibody fragments, and chimeric molecules, e.g., to target agents to platelets and for the treatment or prevention of diseases or disorders are provided.Type: GrantFiled: October 23, 2015Date of Patent: December 29, 2020Assignee: Biogen MA Inc.Inventors: Joe Salas, Karl Hanf, Arjan van der Flier, Bradley R. Pearse
-
Publication number: 20200354459Abstract: Antibodies and antigen-binding antibody fragments that bind to GPIIb/IIIa and chimeric polypeptides comprising these binding molecules are disclosed. Some of these antibodies and antigen-binding antibody fragments preferentially bind GPIIb/IIIa on activated platelets while others do not show a preference for binding GPIIb/IIIa on resting versus activated platelets. Some of these antibodies and antibody fragments do not inhibit the interaction of GPIIb/IIIa with fibrinogen, while some others do. The disclosed antibodies do not induce platelet activation. Some of these antibodies and antigen-binding antibody fragments are useful in targeting therapeutic agents such as clotting factors to platelets while others are useful in reducing platelet aggregation and/or thrombus formation.Type: ApplicationFiled: December 19, 2019Publication date: November 12, 2020Applicant: Biogen MA Inc.Inventors: Bradley Pearse, Joe Salas, Robert Peters, Christilyn Graff
-
Publication number: 20200102391Abstract: The present invention provides antibodies and antigen-binding molecules thereof which specifically bind the ? and/or ? subunits of the non-active form of the GPIIb/IIIIa receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties and used, for example, as targeting moieties. The invention also includes methods for screening for these antibodies, as well as methods of making and methods of using chimeric molecules derived from the antibodies.Type: ApplicationFiled: June 12, 2019Publication date: April 2, 2020Applicant: Biogen MA Inc.Inventors: Joe Salas, Siyuan Tan, Robert Peters
-
Publication number: 20190309280Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disefficacy orders using the disclosed compounds, methods of enhancing in vivo of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.Type: ApplicationFiled: March 18, 2019Publication date: October 10, 2019Inventors: Vu Phong HONG, Adam R. MEZO, Joe SALAS, Robert PETERS
-
Patent number: 10364288Abstract: The present invention provides antibodies and antigen-binding molecules thereof which specifically bind the ? and/or ? subunits of the non-active form of the GPIIb/IIIIa receptor. The antibodies and antigen-binding molecules can be genetically fused and/or conjugated to heterologous moieties and used, for example, as targeting moieties. The invention also includes methods for screening for these antibodies, as well as methods of making and methods of using chimeric molecules derived from the antibodies.Type: GrantFiled: May 23, 2014Date of Patent: July 30, 2019Assignee: Biogen MA Inc.Inventors: Joe Salas, Siyuan Tan, Robert Peters
-
Publication number: 20190225957Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.Type: ApplicationFiled: December 20, 2018Publication date: July 25, 2019Applicant: Bioverativ Therapeutics, Inc.Inventors: Joe SALAS, Elena KISTANOVA, Vu Phong HONG, Adam R. MEZO, Robert T. PETERS
-
Patent number: 10287564Abstract: The present disclosure provides protease-activatable procoagulant compounds comprising a procoagulant polypeptide, e.g., a procoagulant peptide and/or clotting factor, and a linker comprising a protease-cleavable substrate (e.g., a synthetic thrombin substrate) and a self-immolative spacer (e.g., p-amino benzyl carbamate). Upon cleavage of the protease-cleavable substrate by a protease (e.g., thrombin), the self-immolative spacer cleaves itself from the procoagulant polypeptide such that the polypeptide is in an underivatized and active form. Also provided are pharmaceutical compositions, methods for treating bleeding disorders using the disclosed compounds, methods of enhancing in vivo efficacy of procoagulant polypeptides, methods of increasing the efficacy of proteolytic cleavage of compounds comprising procoagulant polypeptides, methods of activating procoagulant polypeptides, and methods of releasing a procoagulant polypeptide from a heterologous moiety such as PEG.Type: GrantFiled: June 7, 2013Date of Patent: May 14, 2019Assignee: Bioverativ Therapeutics Inc.Inventors: Vu Phong Hong, Adam R. Mezo, Joe Salas, Robert T. Peters
-
Patent number: 10202595Abstract: The invention provides chimeric clotting factors comprising an activatable clotting factor and an enhancer moiety. The activatable clotting factor allows the chimeric clotting factor to be activated at the site of coagulation. The enhancer moiety can additionally improve procoagulation activities of the chimeric clotting factors. The chimeric clotting factors can further be improved by fusion to a half-life extender, which improves a pharmacokinetics property of the chimeric clotting factor. The invention also includes methods of making and methods of using these chimeric clotting factors.Type: GrantFiled: June 7, 2013Date of Patent: February 12, 2019Assignee: Bioverativ Therapeutics Inc.Inventors: Joe Salas, Elena Kistanova, Vu Phong Hong, Adam R. Meso, Robert T. Peters